Novel strategies to improve the effectiveness of radiation and targeted therapies in lung cancer

Radiotherapy is the single most common treatment in cancer care, yet its power is deliberately capped to avoid destroying healthy tissue around a tumour. This research programme aims to find ways to make radiation more lethal to lung cancer cells while leaving normal cells unharmed. The core problem is a biological trade-off: higher radiation doses kill more cancer cells but also cause severe damage to the lungs, heart, and oesophagus. Current techniques have largely hit a ceiling. The researchers will test combinations of radiotherapy with targeted drugs—molecules that home in on specific weaknesses in cancer cells—to see if they can tip the balance in favour of tumour destruction without worsening side effects. If successful, this work could change how lung cancer is treated in the NHS. Patients might receive shorter, more effective courses of radiotherapy with fewer complications, reducing hospital visits and improving quality of life during and after treatment. Because radiotherapy is used in most cancer types, any generalisable insight from this lung-focused programme could eventually ripple across oncology, quietly reshaping treatment protocols in clinics worldwide.